Download precision medicine white paper to advance your clinical trial outcomes

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options


precision medicine white paperThe goal of precision medicine is to individualize treatments by tailoring them to the biological characteristics of the patient and his or her disease.

This white paper discusses genomics-based strategies to  advance your precision medicine clinical outcomes. 

Discover  how a comprehensive precision medicine strategy can help you identify the patients who would most likely benefit from a treatment and suffer the least side effects, ensuring  the right drug is used in the right patient at the right time.



Victor Weigman, Ph.D., Director, Translational Genomics, Q2 Solutions

Victor Weigman

Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests. 

Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays.  Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies. 

Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.

Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions

Patrice HugoPatrice Hugo, Ph.D. is chief scientific officer of Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Hugo leads the organization’s global scientific strategy and implementation, developing and accelerating strategies to help improve human health through innovation that transforms science and data into actionable medical insights.  

Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate Vice President and Chief Scientist at Laboratory Corporation of America (LabCorp). He has held several other senior leadership positions at companies including LabCorp, Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory. 

Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.